-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HEC-68498 in Triple-Negative Breast Cancer (TNBC) Drug Details: HEC-68498 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HIV-1 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HIV-1 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HIV-1 in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deflexifol in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deflexifol in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deflexifol in Solid Tumor Drug Details: Deflexifol is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LM-302 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Gastric Cancer Drug Details: LM-302 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JANX-008 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Metastatic Renal Cell Carcinoma Drug Details: JANX-008...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-400 in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-400 in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-400 in Uterine Cancer Drug Details: ABBV-400 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rongliflozin in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rongliflozin in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rongliflozin in Type 2 Diabetes Drug Details: Rongliflozin (HEC-44616) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-88473 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HEC-88473 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: HEC-88473 is under development for the treatment...